- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.10. | J&J in talks to buy immunology partner Protagonist: WSJ | ||
| 10.10. | Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial | ||
| 10.10. | Amid the dip, biotech execs share silver linings in a tumultuous environment | ||
| 10.10. | AstraZeneca: Building a transparent pipeline from the ground up | ||
| 10.10. | BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence | ||
| 10.10. | Shuttle Pharma launches into AI drug discovery space via $10M acquisition | ||
| 10.10. | Inflammation biotech Evommune eyes IPO to fund further dermatitis trials | ||
| 09.10. | 2 ex-Moderna leaders unveil $325M inaugural VC fund for platform biotechs | ||
| 09.10. | Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test | ||
| 09.10. | Expedition resupplies for phase 2 COPD voyage with $165M series A | ||
| 09.10. | AviadoBio secures option to rare eye disease gene therapy that could bring Chinese biotech $413M | ||
| 09.10. | Novo inks Akero buyout worth up to $5.2B to bag late-phase MASH prospect | ||
| 09.10. | CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug | ||
| 08.10. | US government pumps money toward in vivo cell therapy programs | ||
| 08.10. | TransCode rewrites future, securing $25M lifeline and phase 3 cancer vaccine | ||
| 08.10. | Arthrosi raises $153M, fueling dash toward phase 3 gout data in 2026 | ||
| 08.10. | Immunology biotech Nilo launches with $101M and mission to harness neural circuits | ||
| 08.10. | Sanofi's $110M radioligand therapy hits response rate goal in phase 2 tumor trial | ||
| 07.10. | After high-profile FDA exit, Peter Marks lands at Eli Lilly | ||
| 07.10. | Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners | ||
| 07.10. | US government earmarks up to $48M for development of Kernal's mRNA CAR-T | ||
| 07.10. | GLD flexes muscle-wasting ambitions, launching Altagenics with an assist from Heligenics | ||
| 07.10. | James Wilson's GEMMABio launches new gene therapy biotech for 'ultra-orphan' diseases | ||
| 07.10. | MapLight illuminates $262M IPO plans to fund Cobenfy competitor | ||
| 07.10. | AstraZeneca's $1.3B bet yields second phase 3 blood pressure win, bolstering differentiation case |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .